Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €225.06 EUR
Change Today -1.95 / -0.86%
Volume 0.0
PY2 On Other Exchanges
As of 3:41 PM 04/30/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

999 East Arques Avenue

Sunnyvale, CA 94085

United States

Phone: 408-774-0330

Fax: 408-774-0340

Pharmacyclics, Inc. focuses on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. Marketed Product - IMBRUVICA (ibrutinib) IMBRUVICA is approved by the U.S. Food and Drug Administration (FDA) as a single agent for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) who in each case have received at least one prior therapy. The FDA approval for these indications was based on overall response rate (ORR). IMBRUVICA is a new agent that inhibits the function of Bruton's tyrosine kinase (BTK). BTK is a key signaling molecule of the B-cell receptor signaling complex that plays an important role in the survival of malignant B-cells. IMBRUVICA blocks signals that stimulate malignant B-cells to grow and divide uncontrollably. IMBRUVICA became commercially available in the United States in 2013. IMBRUVICA is being marketed principally through a commercial team with relevant expertise in the promotion, distribution and reimbursement of oncology/hematology drugs. In 2013, the company established its commercial organization to support the commercialization of IMBRUVICA in the U.S. The company’s collaboration partner Janssen Biotech, Inc. (Janssen) already has an Oncology Sales Organization in place. IMBRUVICA is being studied in multiple Phase I, II and III studies and continues to be developed for the treatment of other B-cell malignancies. In addition to IMBRUVICA, the company has three other product candidates in clinical development and various preclinical molecules in primary optimization, including a BTK inhibitor targeting anti-inflammatory and autoimmune indications entering the clinic with a Phase I study, an inhibitor of Factor VIIa (PCI-27483) and a Histone deacetylases (HDAC) inhibitor, abexinostat, in Phase I and II clinical trials in solid tumors and hematological malignancies. BTK Inhibitor Program The company engages in the development of orally bioavailable inhibitors of BTK, a signaling protein that is critically important for the activity of B-cells (immune cells that can develop into antibody producing cells). It is using a multi-tier preclinical testing strategy to develop novel inhibitors of BTK for anti-inflammatory and autoimmune diseases. The company developed IMBRUVICA, which has been commercialized for MCL and CLL patients, who in each case have received at least one prior therapy, and has demonstrated clinical activity and tolerability in Phase I, II and III clinical trials in various B-cell malignancies. Factor VII is an enzyme that becomes activated (FVIIa) by binding to the cell surface protein tissue factor (TF), a protein found in the body that helps to trigger the process of blood clotting in response to injury. The company’s Factor VIIa inhibitor PCI-27483 is a first-in-human small molecule inhibitor that selectively targets FVIIa. PCI-27483, claimed as a composition of matter, is covered by granted patents in the U.S., Canada, Japan, China, and India. The company has pending patent applications covering PCI-24783, as compositions of matter, in the U.S., and Europe. As of December 31, 2013, the duration of the granted patents in the U.S., Canada, Japan, China and India that claim PCI-27483 as compositions of matter is through December 2023, subject to any patent term extensions that may be obtained in certain territories. ABEXINOSTAT (PCI-24781) PAN-HDAC INHIBITOR Abexinostat is an orally dosed, broad spectrum, hydroxamic acid-based small molecule HDAC inhibitor that has been evaluated in Phase I and II clinical trials for refractory solid tumors and lymphoma by Pharmacyclics and its ex-U.S. partner, Les Laboratoires Servier of Paris, France (Servier). In 2009, the company entered into a collaboration agreement with Servier, pursuant to which it granted Servier an exclusive license for its pan-HDAC inhibitors, including abexinostat, for territories throughout the world excluding the United States and its possessions. Business Strategy The key elements of the company’s business strategy include focusing on creating novel, patentable, differentiated biopharmac

Page 12Next Page

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PY2:GR €225.06 EUR -1.95

PY2 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.124.00 CHF +0.30
Alexion Pharmaceuticals Inc $172.50 USD +3.27
BioMarin Pharmaceutical Inc $115.92 USD +3.87
Genmab A/S kr514.00 DKK 0.00
Vertex Pharmaceuticals Inc $125.60 USD +2.32
View Industry Companies

Industry Analysis


Industry Average

Valuation PY2 Industry Range
Price/Earnings 100.0x
Price/Sales 26.4x
Price/Book 23.3x
Price/Cash Flow 225.6x
TEV/Sales 25.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMACYCLICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at